



NEWS RELEASE

BIOSYENT RELEASES FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2025

FOR IMMEDIATE RELEASE

MARCH 19, 2026

MISSISSAUGA, ONTARIO (March 19, 2026) BioSyent Inc. ("BioSyent", TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2025. Key highlights include:

(CAD)	Q4 2025	% Change vs. Q4 2024	FY 2025	% Change vs. FY 2024
Canadian Pharma Sales	8,792,653	+3%	37,143,783	+13%
International Pharma Sales	601,387	+240%	3,735,959	+302%
Legacy Business Sales	277,883	+278%	2,172,241	+86%
Total Company Sales	9,671,923	+10%	43,051,983	+23%
EBITDA¹	2,528,561	+13%	12,122,756	+30%
Net Income After Taxes (NIAT)	1,991,788	+23%	9,012,232	+24%
Fully Diluted EPS	0.17	+25%	0.78	+27%

- Return on Average Equity for FY 2025 was 24% as compared to 21% for FY 2024
- During FY 2025, repurchased for cancellation a total of 19,500 common shares under a Normal Course Issuer Bid (NCIB)
- Paid quarterly cash dividends of \$0.05 per common share on March 14, 2025, June 13, 2025, September 15, 2025, and December 15, 2025
- Increased quarterly dividend by 10% to \$0.055 per common share - paid on March 13, 2026
- Generated \$2.4 million in sales in 2025 from international Tibelia[®] (tibolone) assets acquired in 2024
- Completed acquisition of Oral Science Inc., a Canadian owner and distributor of specialized dental hygiene and oral health products, as announced on March 2, 2026

"We finished 2025 with double-digit overall revenue growth in the fourth quarter with continued growth in our Canadian pharmaceutical business and sizable contributions from our international Tibelia[®] business and legacy business," commented Mr. René Goehrum, President and CEO of BioSyent. "For the full year, we are proud to have delivered 23% total Company revenue growth while maintaining a healthy 21% NIAT margin. We continue to invest in our Feramax[®] and Tibella[®] / Tibelia[®] products which were significant drivers of revenue and profit growth both in Canada and internationally during the year. We also continued to invest in our growing Inofolic[®] launch product during the year. Our mature brands, Cathejell[®], RepaGyn[®] and Protect-It[®] continued to deliver profit and cash flows with narrow ongoing investment. BioSyent's track record of 62 consecutive profitable quarters and capital-light, cash-flowing business model have enabled us to build a strong balance sheet and afforded us with maximum flexibility in capital allocation decisions. We are pleased to have deployed our hard-earned capital in our recent acquisition of Oral Science Inc. and we are eager to continue to grow this newly-acquired oral health business along with our pharmaceutical business. We will continue

to invest in growth and product diversification in both of these businesses while returning capital to shareholders through share buybacks and regular cash dividends. I look forward to sharing our progress throughout 2026.”

The CEO’s presentation on the Q4 and FY 2025 Results is available at the following link: www.biosyent.com/investors/

The Company’s Audited Consolidated Financial Statements and Management’s Discussion and Analysis for the fourth quarter and full year ended December 31, 2025 and 2024 will be posted on www.sedarplus.ca on March 19, 2026.

For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit www.tmxmoney.com.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty healthcare company focused on acquiring or in-licensing, marketing and distributing innovative pharmaceutical and oral health products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its Canadian pharma, international pharma, and oral health business units.

As of the date of this press release, the Company has 11,497,447 common shares outstanding.

BioSyent Inc. Consolidated Statements of Comprehensive Income

In Canadian Dollars	Q4 2025	Q4 2024	% Change	FY 2025	FY 2024	% Change
Net Revenues	9,671,923	8,796,684	10%	43,051,983	35,030,897	23%
Cost of Goods Sold	2,225,569	1,641,735	36%	10,088,955	7,174,824	41%
Gross Profit	7,446,354	7,154,949	4%	32,963,028	27,856,073	18%
Operating Expenses and Finance Income/Costs	4,967,966	4,904,040	1%	20,933,016	18,073,575	16%
Net Income Before Tax	2,478,388	2,250,909	10%	12,030,012	9,782,498	23%
Tax (including Deferred Tax)	486,600	637,715	-24%	3,017,780	2,512,394	20%
Net Income After Tax	1,991,788	1,613,194	23%	9,012,232	7,270,104	24%
Net Income After Tax % to Net Revenues	21%	18%		21%	21%	
EBITDA ¹	2,528,561	2,241,112	13%	12,122,756	9,343,012	30%
EBITDA ¹ % to Net Revenues	26%	25%		28%	27%	

BioSyent Inc.
Consolidated Statements of Financial Position

AS AT	December 31, 2025	December 31, 2024	% Change
ASSETS			
Cash, cash equivalents and short-term investments	\$ 28,651,823	\$ 15,940,971	80%
Trade and other receivables	4,456,562	2,906,829	53%
Inventory	6,416,204	5,328,086	20%
Prepaid expenses and deposits	187,977	201,971	-7%
Derivative asset	-	5,790	-100%
Loans receivable - current	80,395	87,433	-8%
CURRENT ASSETS	39,792,961	24,471,080	63%
Long term investments	3,293,957	10,103,571	-67%
Loans receivable - current	61,799	141,140	-56%
Deferred tax asset	510,932	401,166	27%
Property and equipment	982,737	1,200,992	-18%
Intangible assets	4,797,073	5,041,501	-5%
TOTAL NON CURRENT ASSETS	9,646,498	16,888,370	-43%
TOTAL ASSETS	\$ 49,439,459	\$ 41,359,450	20%
LIABILITIES AND SHAREHOLDERS' EQUITY			
CURRENT LIABILITIES	\$ 7,215,608	\$ 5,405,106	33%
NON CURRENT LIABILITIES	758,345	951,159	-20%
Long term debt	-	-	0%
Total Equity	41,465,506	35,003,185	18%
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 49,439,459	\$ 41,359,450	20%

1. **EBITDA** is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization.

A reconciliation of EBITDA to NIAT for the three months and twelve months ended December 31, 2025 and 2024 is provided in the table below:

	Three Months (Q4) Ended December 31		Full Year (FY) Ended December 31	
	2025	2024	2025	2024
EBITDA	2,528,561	2,241,112	12,122,756	9,343,012
Add: Interest Income	187,767	260,088	809,100	1,088,586
Less: Depreciation - Property, Equipment	(70,964)	(72,113)	(272,299)	(281,220)
Amortization of Intangible Assets	(155,498)	(164,207)	(580,192)	(308,728)
Interest Expense	(11,478)	(13,971)	(49,353)	(59,152)
Income Tax Expense	(486,600)	(637,715)	(3,017,780)	(2,512,394)
NIAT	1,991,788	1,613,194	9,012,232	7,270,104

For further information please contact:

Mr. René C. Goehrum

President and CEO

BioSyent Inc.

E-Mail: investors@biosyent.com

Phone: 905-206-0013

Web: www.biosyent.com

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.